Breast Cancer Clinical Trial

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Summary

This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without docetaxel) or atezolizumab and trastuzumab emtansine in participants with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) and locally advanced early breast cancer (EBC), and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically documented HER2-positive and HER2-negative (cohort E only) breast cancer
Metastatic breast cancer that is measurable (Stage 1) or early breast cancer with a primary tumor size greater than (>) 2 centimeter (cm) (Stage 2)
Eastern cooperative oncology group (ECOG) performed status of 0, 1 or 2; 0 or 1 (cohort E only)
Life expectancy of 12 or more weeks
Adequate hematologic and end-organ function
Left ventricular ejection fraction greater than or equal to (>=) 50 percentage (%); >=55% (cohort E only)

Exclusion Criteria:

Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases
Leptomeningeal disease
Pregnancy or lactation
History of autoimmune disease
Prior allogeneic stem cell or solid organ transplantation
Positive test for human immunodeficiency virus (HIV)
Active hepatitis B or hepatitis C

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

98

Study ID:

NCT02605915

Recruitment Status:

Completed

Sponsor:

Hoffmann-La Roche

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 20 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States
University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute
Little Rock Arkansas, 72205, United States
Joliet oncology hematology associates
Joliet Illinois, 60435, United States
Horizon Oncology Research, Inc.
Lafayette Indiana, 47905, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore Maryland, 21287, United States
Karmanos Cancer Center; Department of Oncology
Detroit Michigan, 48201, United States
HCA Midwest Division
Kansas City Missouri, 64132, United States
Montefiore Medical Center, Advanced Women's Health Center, Clinical Trials and Research Unit; Depart
Bronx New York, 10461, United States
Levine Cancer Institute
Charlotte North Carolina, 28204, United States
Duke Cancer Center
Durham North Carolina, 27710, United States
Oncology Hematology Care Inc
Cincinnati Ohio, 45242, United States
St. Luke's University Health Network
Bethlehem Pennsylvania, 18015, United States
Kimmel Cancer Center Thomas Jefferson University
Philadelphia Pennsylvania, 19107, United States
Magee Womens Hospital
Pittsburgh Pennsylvania, 15213, United States
Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street
Chattanooga Tennessee, 37404, United States
West Clinic
Germantown Tennessee, 38138, United States
Tennessee Oncology
Nashville Tennessee, 37203, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Cancer Therapy and Research Center CTRC at UTHSCSA
San Antonio Texas, 78229, United States
Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

98

Study ID:

NCT02605915

Recruitment Status:

Completed

Sponsor:


Hoffmann-La Roche

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider